Sipuleucel-T for the treatment of prostate cancer: Novel insights and future directions

Research output: Contribution to journalArticlepeer-review


Sipuleucel-T, an autologous cellular immunotherapy manufactured from antigen-presenting cells primed to recognize prostatic acid phosphatase, was the first immunotherapy product approved by the US FDA. It was approved for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer after it was shown to provide a survival advantage. Additional studies have examined its use in other clinical settings and in combination with other approved and investigational immunotherapy agents. This review will discuss the pivotal trials leading to approval, will outline some of the biomarkers associated with its efficacy and will review some of the ongoing combination strategies. Maximizing the efficacy of sipuleucel-T through better patient selection or through combination approaches remains the challenge of the future.

Original languageEnglish (US)
Pages (from-to)907-917
Number of pages11
JournalFuture Oncology
Issue number10
StatePublished - Apr 2018


  • biomarkers
  • cancer vaccine
  • castration-resistant prostate cancer
  • immunotherapy
  • prostate cancer
  • sipuleucel-T

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Sipuleucel-T for the treatment of prostate cancer: Novel insights and future directions'. Together they form a unique fingerprint.

Cite this